Search Results 471-480 of 18340 for alopecia

1. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

2. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

3. A Study to Evaluate Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC - Mayo Clinic

   Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

4. A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer Patients - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1),with the exception of alopecia, ...

5. Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA) - Mayo Clinic

   ... alopecia, vitiligo, and the laboratory values defined in the inclusion criteria: Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case ...

6. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

   03) except for subjects with alopecia; subjects receiving luteinizing hormone-releasing hormone agonists may be considered for enrollment after discussion with ...

7. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer - Mayo Clinic

   Recovered from the toxic effects of radiation treatment before study entry, except for alopecia. Absolute neutrophil count (ANC) ≥ 1500 uL; Platelets (PLT) ...

8. A First in Man Trial for Patients With Cancer - Mayo Clinic

   Recovery from adverse effects of prior therapy at time of enrollment to o ≤ Grade 1 (excluding alopecia); Agreement to forego any other chemotherapy ...

9. A Study of Mogamulizumab Combined with Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Subject with vitiligo, alopecia, type I diabetes mellitus, and endocrine deficiencies including hypothyroidism managed with replacement hormones including ...

10. Belantamab, Lenalidomide, and Daratumumab for Newly-diagnosed Multiple Myeloma - Mayo Clinic

    ... alopecia. Exclusion Criteria: Ability to understand the study procedures and provide written informed consent. Negative hepatitis B test (defined by a ...